With Porous, Perforated, Apertured, Or Sieved Layer (e.g., Dialyzing Layer, Microporous Layer, Etc.) Patents (Class 424/473)
  • Patent number: 10765674
    Abstract: This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: September 8, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Lieven Elvire Colette Baert, Paulus Joannes Lewi, Jan Heeres
  • Patent number: 10765721
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 8, 2020
    Assignee: Ferring B.V
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Patent number: 10647669
    Abstract: Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, ?-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to ?-carotene is 1:0.1-100. In the present invention, by cooperatively using lutein/lutein ester and ?-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 12, 2020
    Assignee: SinoNutraceutical Co., Ltd.
    Inventors: Maojian Gu, Jianmei Su
  • Patent number: 10646468
    Abstract: A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid.is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: May 12, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kentaro Furumoto, Koji Shiraki, Tomoaki Hirayama
  • Patent number: 10525003
    Abstract: The invention provides a topical liquid antifungal composition containing an antifungal agent, a film-forming agent and a solvent. The composition is applied on the infected skin area to form a film that delivers the active agent. The invention also provides a method for treating a fungal infection on the skin by applying the topical antifungal composition that forms a film on the skin.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: January 7, 2020
    Inventor: Friedrich Karl Mayer
  • Patent number: 10463633
    Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: November 5, 2019
    Assignee: KemPharm, Inc.
    Inventor: Subhash Desai
  • Patent number: 10307497
    Abstract: A disinfectant appliance has a plurality of chlorite absorbent particles, a plurality of redox resin particles, and at least one absorbent material combined such that the absorbent material allows and can promote: infusion of water into the disinfectant appliance; release of the chlorite from the chlorite absorbent particles into the water to form a chlorite comprising solution; contacting of the chlorite comprising solution with the redox resin particles; and the expulsion of ClO2 comprising solution from the disinfectant appliance onto a surface to be disinfected. The disinfectant appliance can include a storage section and can include a handle. The disinfectant appliance can be in the form of a wipe or sponge that can be contacted with a surface suspected of being infected.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 4, 2019
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: David Ernest Richardson
  • Patent number: 10272031
    Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 30, 2019
    Inventor: Zi-Qiang Gu
  • Patent number: 10265245
    Abstract: A portable drug dispenser includes a chamber for holding a plurality of separately contained drug products, a dispensing mechanism for dispensing one or more of the plurality of drug products, and may optionally include a processor to determine the time of each activation of the dispensing mechanism and to transmit the determined time of activation to a computer located remote to the dispenser. The dispenser may include more than one chamber for holding drugs.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: April 23, 2019
    Inventors: Daniel L. Kraft, Scott Parazynski
  • Patent number: 10226447
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin. The dosage form is effective to release melatonin therefrom for at least six hours after oral ingestion.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 12, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 10195114
    Abstract: The present invention relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps, sutures, and endotracheal devices. The invention also generally relates to a method for extruding multiple laminated flow streams using microlayer coextrusion to create these various time-release drug delivery products.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: February 5, 2019
    Inventors: Richard R. Guillemette, Robert G. Peters, Christopher Hummel
  • Patent number: 10172842
    Abstract: The present invention provides a sustained release oral dosage form containing dalfampridine that can be administered once daily. The dosage form includes dalfampridine as the active pharmaceutical ingredient and the excipients comprising osmotic agents in a tablet core. The sustained release oral dosage form of the present invention can be administrated once daily and can provide a proper fluctuation index to reduce undesired adverse effect, prevent alcohol-induced dose dumping and release drug at a rate sufficient to maintain certain drug plasma concentration.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: January 8, 2019
    Assignee: PharmaDax Inc.
    Inventors: Chih-Yao Yang, Jen-Sen Wu, Shih-Wei Huang, Yi-Chen Tsai, Chieh-Wen Chang, Cheng-Wei Chang
  • Patent number: 10092519
    Abstract: Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: October 9, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Glenn Van Buskirk, Mark Chasin, Hua-Pin Huang, Vijay Vashi
  • Patent number: 10071060
    Abstract: A tablet for the controlled release of a drug. The tablet is in the form of an asymmetrically coated tablet so that immediate release or time-delayed release times can be precisely controlled and the extended release slab may provide zero-order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations. The core of the tablet is coated with an asymmetrical coating, that is, a coating with regions having different properties. The coatings may include drugs in varying concentrations. Further, different regions of the coating may have different rates of dissolution. The core of the tablet may be provided with a constant cross-sectional area along a longitudinal length of the tablet, a coating having a first region with a more rapid rate of dissolution than a second region. The dissolution of the first region exposes only the cross-sectional area to the dissolution medium.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 11, 2018
    Assignee: BioVentures, LLC
    Inventor: Cherng-ju Kim
  • Patent number: 10064873
    Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: September 4, 2018
    Inventor: Brian Alvin Johns
  • Patent number: 10058633
    Abstract: In some embodiments, the present invention provides compositions that comprise: (1) a biodegradable polymer matrix; and (2) at least one biodegradable reinforcing particle that is dispersed in the matrix. In some embodiments, the biodegradable reinforcing particle is selected from the group consisting of porous oxide particles and porous semiconductor particles. In additional embodiments, the compositions of the present invention further comprise a (3) porogen particle that is also dispersed in the matrix. In further embodiments, the compositions of the present invention are also associated with one or more active agents. In various embodiments, the active agents are associated with the biodegradable polymer matrix, the biodegradable reinforcing particle, and/or the porogen particle. In various embodiments, the compositions of the present invention may be utilized as scaffolds, such as scaffolds for treating bone defects.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 28, 2018
    Assignee: Board of Regents of the University of Texas System
    Inventors: Mauro Ferrari, Rachel Buchanan, Christine Smid, Ennio Tasciotti
  • Patent number: 9993432
    Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: June 12, 2018
    Inventors: Alexander Kuhl, Erich Brendel, Frank Bröcker, Adrian Funke, Andreas Ohm, Dennis Kvesic, Thomas Volkmer
  • Patent number: 9974752
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 22, 2018
    Assignee: PURDUE PHARMA
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 9937157
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 10, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Patent number: 9795538
    Abstract: Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: October 24, 2017
    Inventor: John Puckett
  • Patent number: 9750696
    Abstract: The present invention relates to controlled-release pharmaceutical dosage forms comprising a solid dispersion of a poorly water-soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled-release dosage forms.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: September 5, 2017
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Sandeep Kumar Vats, Kalaiselvan Ramaraju, Romi Barat Singh
  • Patent number: 9724362
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: August 8, 2017
    Assignee: Bend Research, Inc.
    Inventors: Warren Kenyon Miller, Daniel Smithey, Benjamin Lee Frankamp, Ralph Tadday
  • Patent number: 9718704
    Abstract: The group of inventions relates to the field of organic chemistry and can be used for cleaning water, industrial and domestic waste water or waste water sediment, and for the containment and recovery of petroleum and petroleum product spills in large bodies of water, rivers, lakes and seas. In the claimed group of inventions, aqueous solutions of polysaccharide microgels, having a molecular mass of 20000-200000 daltons and a particle size of 50-600 nm, are used as a substance for cleaning water of petroleum and petroleum products. Moreover, low concentrations of polysaccharide microgels in water, ranging from 0.1 to 20 g/l, are used. Said solutions are used as a surface modifier for a filter used in separating water-oil emulsions, as a sorbent for the containment and recovery of oil spills in an aqueous medium, and also as a coagulant for the cleaning of water polluted by petroleum and petroleum products.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: August 1, 2017
    Assignee: Obshchestvo S Ogranichennoj Otvetstvennostyu “NPO Biomikrogeli”
    Inventors: Andrey Aleksandrovich Elagin, Maksim Anatolevich Mironov, Vladislav Sergeevich Ponomarev
  • Patent number: 9642806
    Abstract: The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: May 9, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Lieven E. C. Baert, Geert Verreck, Dany Thone
  • Patent number: 9642809
    Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: May 9, 2017
    Assignee: EGALET LTD.
    Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
  • Patent number: 9622977
    Abstract: Controlled release dosage forms comprising a pharmaceutically active agent capable of not more than 90% release in 12 hours in a simulated gastric juice in first order release rate USP type 1 dissolution test, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, the pharmaceutically active agent and excipients; the tablet capable of rapid swelling without disintegration in simulated gastric juice to a size resulting in gastric retention in the stomach and controlled release of the active agent by controlled erosion and diffusion immediately after coming into contact with the gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative or CARBOPOL® incorporating the active agent which is not a polymeric molecule and after administration in stomach, the microspheres adhere to the gastric mucosa for a long and controlled time release of the active agent.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: April 18, 2017
    Inventors: Subheet Jain, Sumeet Dhaliwal, Madhu Rana, Hardevinder Pal Singh, Ashok Kumar Tiwary
  • Patent number: 9511037
    Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e g, immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: December 6, 2016
    Inventor: Subhash Desai
  • Patent number: 9468604
    Abstract: In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 18, 2016
    Assignee: Bend Research, Inc.
    Inventors: Dwayne T. Friesen, Michael J. Gumkowski, Rodney James Ketner, Douglas A. Lorenz, James A. S. Nightingale, Ravi M. Shanker, James B. West
  • Patent number: 9248119
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Patent number: 9205426
    Abstract: A biochip includes: a chamber that has a longitudinal direction; a holding unit that holds a liquid sample within a predetermined area of the chamber provided along the longitudinal direction, and releases the liquid sample from the predetermined area to an area inside the chamber by using a predetermined pressing force; and a pressed member that applies the predetermined pressing force to the liquid sample.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 8, 2015
    Assignee: Seiko Epson Corporation
    Inventor: Hiroshi Koeda
  • Patent number: 9192590
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9180045
    Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: November 10, 2015
    Assignee: Mati Therapeutics Inc.
    Inventor: Eliot Lazar
  • Patent number: 9149472
    Abstract: A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 6, 2015
    Inventor: Jack William Schultz
  • Patent number: 9149460
    Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: October 6, 2015
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Vlasta Humar, Mateja Burjak, Rok Grahek, Mateja Salobir, Janez Kerc, Klemen Kocevar
  • Patent number: 9132096
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: September 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Patent number: 9079004
    Abstract: An access port for providing subcutaneous access to a patient is disclosed. In one embodiment, the port includes an internal body defining a fluid cavity that is accessible via a septum. A compliant outer cover including silicone is disposed about at least a portion of the body. A flange is included with the port body and is covered by the outer cover. The flange radially extends about a perimeter of the port body proximate the septum so as to impede penetration of a needle substantially into the outer cover in instances where the needle misses the septum. The flange can further include both an anchoring feature for securing the outer cover to the port body and an identification feature observable via x-ray imaging technology for conveying information indicative of at least one attribute of the access port. The outer cover provides a suitable surface for application of an antimicrobial/antithrombotic coating.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: July 14, 2015
    Assignee: C. R. Bard, Inc.
    Inventors: Martha Wiley, Jodie L. Noyce, David M. Cise, William R. Barron, Kelly J. Christian, Amir Orome
  • Patent number: 9050391
    Abstract: The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: June 9, 2015
    Assignee: NEXILIS AG
    Inventors: Falko Schlottig, Matthias Schnabelrauch, Armin Rex Kautz
  • Patent number: 9028870
    Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: May 12, 2015
    Assignee: Bend Research, Inc.
    Inventors: Leah E. Appel, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Kelly L. Smith, Avinash G. Thombre
  • Patent number: 8992962
    Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: March 31, 2015
    Assignee: Intarcia Therapeutics Inc.
    Inventors: Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
  • Patent number: 8962019
    Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: February 24, 2015
    Assignee: Angelini Pharma, Inc.
    Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
  • Patent number: 8956654
    Abstract: An osmotic dosage form which comprising: (a) a core comprising a biologically active ingredient; (b) a semi-permeable membrane covering said core; and (c) at least one passageway through the semi-permeable membrane, wherein the semi-permeable membrane comprises ethyl cellulose, an acrylic or methacrylic polymer and a water-soluble plasticizer with the proviso that the semi-permeable membrane comprises no or not more than 15 weight percent of a water-soluble material excluding any water-soluble plasticizer, based on the total dry weight of the semi-permeable membrane.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: February 17, 2015
    Assignee: Dow Global Technologies LLC
    Inventors: Yong Gan, Chunliu Zhu, Sophie Zhai, Robert I. Schmitt, Ka Chun A. Chan
  • Patent number: 8936810
    Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 20, 2015
    Assignee: ALZA Corporation
    Inventors: Steven F. Stone, Johan H. Geerke
  • Patent number: 8920835
    Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 30, 2014
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, QILU Pharamceutical Co., Ltd.
    Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
  • Publication number: 20140335178
    Abstract: The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 13, 2014
    Inventor: Richard G. Nause
  • Publication number: 20140302141
    Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.
    Type: Application
    Filed: February 24, 2014
    Publication date: October 9, 2014
  • Publication number: 20140271842
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • Patent number: 8792071
    Abstract: A cellulose acylate film containing a cellulose acylate having a total degree of substitution of from 1.5 to 2.6 and a polycondensate ester, satisfying 3.4?Rth(550)/d, 40 nm?Re(550)?60 nm and 100 nm?Rth(550)?300 nm, having a film thickness of from 20 to 45 ?m and having an internal haze of from 0.005 to 0.07% (d means the film thickness (?m)).
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 29, 2014
    Assignee: Fujifilm Corporation
    Inventors: Hirofumi Toyama, Jun Takeda, Yoshiaki Hisakado, Yoji Ito
  • Patent number: 8747897
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: June 10, 2014
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P. Bhatt
  • Patent number: 8733368
    Abstract: A device which facilitates the absorption of nicotine in order to reduce the incidence of tobacco smoking is disclosed. The device includes a tube defining an interior space. The tube has a first end with an opening and a second end. An inhalable, flowable liquid or gel composition is disposed in the interior space of the tube. The composition may include water, at least one vitamin, a flavoring agent, and nicotine. The flavoring agent may include an intense sweetener such as sucralose, and a natural or artificial fruit flavor. A user inhales on the first end of the tube of the device as a substitute oral activity to tobacco smoking and thereby ingests a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: May 27, 2014
    Assignee: Smoke-Break, Inc.
    Inventors: Brett J. Roth, Terrill S. Clayton
  • Patent number: 8703193
    Abstract: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: April 22, 2014
    Assignee: Cosci Med-Tech Co. Ltd.
    Inventors: Jingang Wang, Haisong Jiang